Clinical Trial Detail

NCT ID NCT02453594
Title Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.